Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New evidence eases some concerns about bone fracture risk with breast cancer drug

24.09.2003


New evidence about the breast cancer drug anastrozole (Arimidex) shows that the incidence of a major side-effect – bone fractures – appears to stabilise after reaching a peak at two years of treatment, easing some of the concerns about the drug.



This finding is the latest to come from evidence provided by the world’s largest international study of breast cancer treatment, the ATAC[1] trial, which compared the aromatase inhibitor anastrozole with breast cancer’s current gold standard hormone treatment tamoxifen, and with both treatments combined.

The trial, involving more than 9,000 post menopausal women in 21 countries, last year revealed that over a median follow-up of patients of 33 months, anastrozole enhanced disease-free survival by 19% and cut the incidence of new tumours in the opposite breast by 58% compared to tamoxifen. This represented an absolute difference of 1.8% in favour of anastrozole. An update at 47 months median follow up showed that the gap had widened to an absolute difference of 2.6% in favour of the newer drug. Overall survival comparisons from the trial should be available next year.


Professor Anthony Howell, chairman of the ATAC steering committee, told a news briefing at ECCO 12 – the European Cancer Conference, that while it was clear that further results were adding to the evidence that anastrozole may in the future supplant tamoxifen doctors needed to be cautious. "We should still wait for that overall survival data next year," he said.

A concern about anastrozole has been the risk of bone fractures. Depriving the body of oestrogen reduces the risk of breast cancer recurring because many breast cancers ’feed’ off this hormone. But, one consequence of oestrogen deprivation is that bones become vulnerable. Aromatase inhibitors such as anastrozole produce profound oestrogen deprivation so it would not be unexpected that women on anastrozole might be more at risk of fractures than those on tamoxifen, a drug that is known to have a mildly positive effect on bone density. Therefore, bone fracture was a pre-defined adverse event in ATAC’s main protocol and one of the important questions posed in the trial was – if anastrozole turned out to be better than tamoxifen at preventing recurrence of breast cancer or of primary tumours in the other breast, would this benefit outweigh the downside of any added incidence of fractures?

Patients’ fracture rates were assessed every six months as a proportion of patients with a first fracture, and these analyses were repeated for fractures of the hip, spine and wrist.

Prof. Howell, a medical oncologist at the Christie Hospital, Manchester, UK said: "We found that at the first analysis, after 31 months median duration of treatment, the incidence of fractures was 5.9% in anastrozole patients compared with 3.7% in tamoxifen patients – nearly 60% greater. But, when the data was updated at 37 months the incidence was 7.1% versus 4.4%, so still around a 60% difference. The risk had not worsened. In fact, the six monthly fracture rates for anastrozole reached a plateau after 24 months with the maximum difference between the two treatments being seen at 18 and 24 months. By the last follow up at 48 months the increase in risk was down to about a third higher for anastrozole. There were similar patterns for fractures of the hip, spine and wrist."

Prof. Howell said: "Anastrozole does lead to an increased bone fracture incidence compared to tamoxifen. But, the positive news is that the fracture rate does appear to peak and then stabilise. So, the overall benefit for patients with early breast cancer remains with anastrozole. We have no idea why the fracture rate stabilises but clearly this is important for patients. It is possible that it will climb again but since the curves have been parallel for some time this seems unlikely.

"It is now important to see what happens when patients stop their treatment after five years and we plan to do bone density measurements at the end of the trial."

The trial shows that the combination of tamoxifen and anastrazole is equivalent to tamoxifen (possibly because anastrozole lowered oestrogen dramatically and there was some evidence that tamoxifen acted as an oestrogen agonist in a low oestrogen environment). It was potentially detrimental, Prof. Howell said, for patients to switch from tamoxifen to anastrozole so the advice was that patients should continue with whichever drug they were on.

He concluded: "It is important that tamoxifen does not suffer from the comparison in this trial because it is still a very good treatment. In developing countries with limited resources to pay for more expensive new drugs it is particularly appropriate to continue to use tamoxifen."



Note: ATAC = Arimidex, Tamoxifen Alone or in Combination. Anastrozole (Arimidex) is an aromatase inhibitor, a class of compounds that inhibit the synthesis of oestrogens from androgens in post-menopausal women.

Further information:
ECCO 12 press office: Sunday 21 September – Thursday 25 September
Tel: 45-3252-4163 or 45-3252-4179
Fax: 45-32524171
Margaret Willson: mobile: 44-797-385-3347 Email: m.willson@mwcommunications.org.uk
Mary Rice: mobile: 44-780-304-8897 Email: mary.rice@blueprintpartners.be
Emma Mason: mobile: 44-771-129-6986 Email: wordmason@aol.com

Margaret Willson | EurekAlert!
Further information:
http://www.fecs.be/

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

New pop-up strategy inspired by cuts, not folds

27.02.2017 | Materials Sciences

Sandia uses confined nanoparticles to improve hydrogen storage materials performance

27.02.2017 | Interdisciplinary Research

Decoding the genome's cryptic language

27.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>